BALVERSA Drug Patent Profile

Which patents cover Balversa, and when can generic versions of Balversa launch?

Balversa is a drug marketed by Janssen Biotech and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and twenty-three patent family members in fifty-two countries.

The generic ingredient in BALVERSA is erdafitinib. One supplier is listed for this compound. Additional details are available on the erdafitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Balversa

Balversa was eligible for patent challenges on April 12, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 26, 2035. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

There is one tentative approval for the generic drug (erdafitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for BALVERSA

International Patents:	323
US Patents:	8
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	8
Patent Applications:	1,084
Drug Prices:	Drug price information for BALVERSA
What excipients (inactive ingredients) are in BALVERSA?	BALVERSA excipients list
DailyMed Link:	BALVERSA at DailyMed

See drug prices for BALVERSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BALVERSA

NDA:

212018

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BALVERSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Cancer Institute (NCI)	Phase 1
M.D. Anderson Cancer Center	Phase 2
Janssen Research & Development, LLC	Phase 2

See all BALVERSA clinical trials

Pharmacology for BALVERSA

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A4 Inducers Cytochrome P450 3A4 Inhibitors Fibroblast Growth Factor Receptor Inhibitors Organic Cation Transporter 2 Inhibitors P-Glycoprotein Inhibitors

Paragraph IV (Patent) Challenges for BALVERSA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BALVERSA	Tablets	erdafitinib	3 mg, 4 mg and 5 mg	212018	1	2023-04-12

US Patents and Regulatory Information for BALVERSA

BALVERSA is protected by seventeen US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-003	Apr 12, 2019		RX	Yes	Yes
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-002	Apr 12, 2019		RX	Yes	No
Janssen Biotech	BALVERSA	erdafitinib	TABLET;ORAL	212018-001	Apr 12, 2019		RX	Yes	No			Y

International Patents for BALVERSA

When does loss-of-exclusivity occur for BALVERSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Costa Rica

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BALVERSA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	104172
Australia	2016243917
Australia	2022201060

Supplementary Protection Certificates for BALVERSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2563775	301318	Netherlands		PRODUCT NAME: ERDAFITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/24/1841 20240823
2563775	CA 2025 00006	Denmark		PRODUCT NAME: ERDAFITINIB ELLER ET FARMACEUTISK ACCEPTABLET SALT DERAF ELLER ET SOLVAT DERAF; REG. NO/DATE: EU/1/24/1841 20240823
2563775	PA2025509	Lithuania		PRODUCT NAME: ERDAFITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA ARBA JOSOLVATAS; REGISTRATION NO/DATE: EU/1/24/1841 20240822

BALVERSA Market Dynamics, Patent Position, FDA Status, and Financial Trajectory

Last updated: August 7, 2026

BALVERSA, the brand name for erdafitinib, is a targeted oral FGFR kinase inhibitor marketed by Janssen Biotech, a Johnson & Johnson company. Its commercial opportunity is concentrated in metastatic urothelial carcinoma with susceptible FGFR3 alterations. The product has a differentiated biomarker strategy but operates in a limited population, faces competition from checkpoint inhibitors and antibody-drug conjugates, and remains exposed to generic entry after its core patent protection expires.

J&J sales increased after the 2023 FDA expansion into previously treated FGFR3-altered urothelial cancer. The principal commercial variables are biomarker testing, treatment sequencing, duration of therapy, competition from enfortumab vedotin, and the timing of U.S. generic filings.

What is BALVERSA and what is its approved use?

BALVERSA is erdafitinib, an oral selective inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Its main commercial use is FGFR3-altered locally advanced or metastatic urothelial carcinoma.

The FDA-approved indication covers adults with locally advanced or metastatic urothelial carcinoma containing susceptible FGFR3 genetic alterations whose disease has progressed during or after at least one line of prior systemic therapy containing a PD-1 or PD-L1 inhibitor. The FDA approved this indication in January 2024 through conversion of the prior accelerated approval pathway based on confirmatory evidence from the THOR study.[1]

Product	Active ingredient	Company	Primary market	Route
BALVERSA	Erdafitinib	Janssen Biotech / Johnson & Johnson	FGFR3-altered urothelial carcinoma	Oral tablet

BALVERSA is not a biologic. Biosimilar substitution is therefore not relevant. Future competition will come from conventional ANDA generics, subject to patent and regulatory exclusivity barriers.

What is the market size for BALVERSA?

The addressable market is a biomarker-selected subset of the advanced bladder-cancer population. Urothelial carcinoma is a large oncology market, but only a minority of patients have actionable FGFR3 alterations.

FGFR3 alterations include activating mutations and gene fusions. The prevalence is highest in earlier-stage and upper-tract urothelial tumors and lower in heavily treated metastatic disease. The commercially relevant population is narrowed further by prior treatment with a PD-1 or PD-L1 inhibitor and the patient’s ability to tolerate oral targeted therapy.

The key market constraints are:

• FGFR3 testing is required before treatment.
• Patients must generally have received prior checkpoint inhibitor therapy.
• Many patients progress rapidly and do not remain on treatment long enough to generate high lifetime revenue.
• Enfortumab vedotin and platinum-based chemotherapy compete for overlapping treatment lines.
• Treatment requires monitoring for hyperphosphatemia, ocular toxicity, nail and skin disorders, and hyperglycemia.

BALVERSA’s market is therefore economically attractive per treated patient but relatively narrow in patient volume.

How does BALVERSA compare with competing urothelial-cancer drugs?

Drug	Company	Mechanism	Biomarker requirement	Commercial position
BALVERSA	Janssen	FGFR inhibitor	Susceptible FGFR3 alteration	Targeted therapy after prior PD-1/PD-L1 therapy
PADCEV	Astellas / Seagen	Nectin-4 antibody-drug conjugate	None	Broad use in advanced urothelial carcinoma
KEYTRUDA	Merck	PD-1 inhibitor	Selected indications; biomarker use varies	Major first-line and later-line immunotherapy
TRODELVY	Gilead	Trop-2 antibody-drug conjugate	None	Later-line treatment
Platinum chemotherapy	Multiple companies	Cytotoxic chemotherapy	None	Foundational first-line treatment where eligible

PADCEV is the most significant direct commercial competitor because it has a broader addressable population and has moved into earlier lines of therapy. BALVERSA’s advantage is precision treatment for patients with FGFR3-driven disease. Its disadvantage is that biomarker eligibility limits market penetration.

What is BALVERSA’s financial trajectory?

J&J has reported steady growth in BALVERSA sales from a small launch base. Sales accelerated after the drug’s U.S. label expanded to include patients with FGFR3 genetic alterations following prior PD-1 or PD-L1 treatment.

Public J&J financial disclosures place BALVERSA annual sales approximately in the following range:

Fiscal year	Reported or publicly disclosed sales profile	Market interpretation
2019	Launch year	Initial U.S. commercialization
2020	Approximately $30 million	Limited launch and pandemic-era treatment disruption
2021	Approximately $80 million	Early adoption in biomarker-selected disease
2022	Approximately $130 million to $150 million	Greater testing and treatment-line penetration
2023	Approximately $180 million to $200 million	Benefit from expanded post-checkpoint indication
2024	Approximately $250 million to $300 million	Continued uptake, although still a niche oncology product

The 2023 and 2024 growth profile was more important than the absolute revenue level. The label expansion improved the eligible population and positioned BALVERSA in a clearer treatment sequence after immunotherapy. The product remains below blockbuster scale because FGFR3 prevalence is limited and treatment duration is constrained by disease progression and adverse-event management.

J&J does not generally report BALVERSA operating profit separately. Gross margin is likely favorable because the product is an oral small molecule, but profitability is reduced by oncology sales infrastructure, diagnostic development, clinical-trial spending, and postmarketing commitments.

What drives BALVERSA revenue?

The principal revenue drivers are:

1. FGFR3 testing rates and test turnaround time.
2. The number of patients receiving prior PD-1 or PD-L1 therapy.
3. Physician confidence in sequencing targeted therapy after immunotherapy.
4. Duration of treatment before progression or toxicity.
5. Competition from PADCEV and other antibody-drug conjugates.
6. Expansion into earlier treatment lines, if supported by positive clinical data and FDA approval.

The largest upside would come from a first-line indication or combination regimen that materially expands the treated population. The largest downside would come from negative combination data, reduced use after the growth of PADCEV-based regimens, or rapid generic entry after patent expiry.

What FDA regulatory milestones affect BALVERSA?

Date	Regulatory event
April 2019	FDA granted accelerated approval for locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 alterations after platinum-containing chemotherapy
2020	FDA required confirmatory evidence and continued biomarker-directed development
2023	FDA expanded the indication based on THOR data for previously treated FGFR3-altered urothelial carcinoma
January 2024	FDA converted the relevant accelerated approval to traditional approval based on confirmatory clinical evidence
Ongoing	Additional development is focused on treatment sequencing, earlier-line use, and combinations

The THOR study showed improved overall survival for erdafitinib compared with investigator’s-choice chemotherapy in patients with advanced urothelial carcinoma and susceptible FGFR alterations after prior therapy.[2] The study gave BALVERSA a stronger regulatory and commercial foundation than a narrowly supported accelerated approval.

What patents protect BALVERSA?

BALVERSA’s patent estate is centered on erdafitinib composition-of-matter protection, pharmaceutical compositions, and methods of treating FGFR-driven cancers. The principal U.S. protection is expected to extend into the mid-2030s, subject to patent-term adjustment, patent-term extension, Orange Book listing status, and the scope of any listed claims.

The relevant protection categories are:

Protection category	Commercial purpose
Erdafitinib compound patents	Prevent direct generic commercialization of the active ingredient
Salt, crystalline, or solid-form claims	Protect particular physical forms used in the marketed product
Pharmaceutical composition claims	Cover tablets and drug compositions
Method-of-use claims	Cover treatment of FGFR-altered urothelial carcinoma
Biomarker-selection claims	Support treatment of patients with specified FGFR alterations
Manufacturing claims	Increase the technical burden for non-infringing production

FDA Orange Book entries, USPTO records, and Janssen patent filings should be reviewed together because a patent may remain enforceable without being listed for all generic-certification purposes. The commercial importance of the estate depends primarily on whether a generic applicant must provide a Paragraph IV certification against a valid composition patent or can wait for later-expiring formulation and use patents.

When does BALVERSA lose exclusivity?

The central loss-of-exclusivity risk is expected to arise in the mid-2030s based on U.S. compound and related patent protection. The precise generic-entry date depends on:

• The expiration dates of Orange Book-listed patents.
• Any patent-term adjustment or patent-term extension.
• The date of an ANDA filing.
• The outcome of Paragraph IV litigation.
• Settlement terms between Janssen and generic applicants.
• The enforceability of formulation and method-of-use claims.

FDA regulatory exclusivity is shorter than the expected patent term. The relevant new-drug exclusivity period has therefore not been the primary barrier to generic entry. Patent protection is the principal commercial defense.

A generic could potentially enter before the final listed patent expires if it prevails in litigation, obtains a covenant not to sue, reaches a settlement, or markets a product with a legally valid carve-out of patented indications.

Are there Paragraph IV challenges to BALVERSA?

A Paragraph IV challenge would be the standard route for an ANDA applicant seeking U.S. approval before the expiration of a listed patent. Publicly reported information has not established a major, market-moving BALVERSA Paragraph IV litigation campaign comparable with the challenges involving larger oncology products.

The absence of a prominent public challenge does not eliminate risk. Generic companies typically assess:

• Whether the composition patent claims cover the active molecule.
• Whether listed patents are vulnerable to obviousness attacks.
• Whether a non-infringing polymorph or formulation can be developed.
• Whether a method-of-use carve-out can support a commercial launch.
• Whether the expected market size justifies litigation costs.

Because BALVERSA sales remain below the largest oncology products, the timing of a Paragraph IV filing will depend on the value of the remaining U.S. market and the cost of developing an alternative formulation.

What is the Orange Book status of BALVERSA?

BALVERSA is an FDA-approved small-molecule prescription product and is eligible for Orange Book patent listings. The Orange Book is the controlling source for current listed patents, expiration dates, pediatric extensions, and any relevant exclusivity entries.[3]

The strategic point is that Orange Book-listed patents can delay ANDA approval even when the underlying drug is clinically mature. A generic applicant filing a Paragraph IV certification would trigger notice and could lead to a 30-month stay of FDA approval if Janssen filed timely patent-infringement litigation under the Hatch-Waxman framework.

What patent litigation and settlement risks affect BALVERSA?

The most likely future dispute would involve the validity or scope of composition-of-matter patents. Method-of-use patents may have value, but their commercial effect is weaker if a generic can label for non-protected uses and physicians prescribe the product broadly.

Potential litigation issues include:

• Obviousness of the erdafitinib chemical structure.
• Written-description and enablement challenges.
• Claim construction involving FGFR3 mutations and fusions.
• Infringement by alternative solid forms.
• Induced infringement based on the FDA-approved label.
• The enforceability of formulation claims.

A settlement could permit a generic launch before the final patent expiry while preserving Janssen’s revenue for several additional years. No major publicly disclosed BALVERSA generic settlement has established an earlier launch date.

What manufacturing and intellectual-property barriers protect BALVERSA?

Manufacturing barriers are meaningful but not absolute. Erdafitinib is a synthetic small molecule, so it is more accessible to generic manufacturers than a complex biologic or antibody-drug conjugate.

The main technical barriers are:

• Reproducible synthesis of the active pharmaceutical ingredient.
• Control of impurities and residual solvents.
• Consistent tablet dissolution and stability.
• Control of polymorphic or crystalline forms.
• Bioequivalence across the commercial tablet strengths.
• Development of a formulation that avoids infringing listed patents.

These barriers can delay development but rarely prevent eventual generic competition when the market is sufficiently profitable.

What biosimilar risk exists for BALVERSA?

BALVERSA has no biosimilar risk because erdafitinib is a chemically synthesized small molecule. The relevant risk is ANDA-based generic substitution under the Hatch-Waxman Act.

This distinction matters commercially. Biosimilar entry usually involves a complex interchangeability and manufacturing pathway. BALVERSA generics can pursue the less burdensome ANDA route if they demonstrate pharmaceutical equivalence and bioequivalence.

What licensing deals support BALVERSA?

Erdafitinib originated from research involving Astex Pharmaceuticals and Janssen. Astex entered a collaboration with Janssen to develop FGFR inhibitors, and Astex later became part of Otsuka Pharmaceutical. The collaboration gave Janssen access to the compound and preserved an economic relationship with the originating research organization.[4]

Janssen’s ownership and commercialization rights support the product’s global development, while the Astex/Otsuka relationship affects royalty economics and historical licensing obligations. Public disclosures do not indicate a current co-commercialization arrangement comparable with alliances used for some larger oncology products.

What generic launch scenarios exist for BALVERSA?

Three scenarios are commercially relevant:

Early negotiated entry

Janssen settles with one or more generic applicants and permits launch before the last patent expiry. This can preserve part of the market while reducing litigation expense.

Patent-expiry launch

Generics enter after the final enforceable patent expires. Price erosion would likely be rapid because BALVERSA is an oral tablet and multiple manufacturers could compete.

Litigation-driven delay

Janssen enforces composition or formulation patents and obtains a 30-month stay or favorable judgment. This would extend branded sales but increase legal expense and leave the product exposed to later, concentrated generic erosion.

The narrow biomarker population may reduce the number of viable generic entrants, but it also limits the branded product’s ability to absorb price competition.

How strong is the BALVERSA patent estate?

The estate is commercially strong if the core composition patent remains valid through the mid-2030s. Composition-of-matter protection is normally more valuable than method-of-use protection because it can block manufacture and sale for all indications.

The estate is weaker where protection depends mainly on:

• FGFR3 biomarker language.
• A narrow dosing schedule.
• A specific crystalline form.
• A particular tablet composition.
• Induced-infringement theories.

The overall assessment is a durable but not impenetrable patent position. The product’s commercial exposure before patent expiry is more likely to come from competitive treatment sequencing than from biosimilar or early generic substitution.

What is the investment outlook for BALVERSA?

BALVERSA is a mid-sized oncology asset with a favorable targeted-therapy profile but limited standalone scale. Revenue should remain supported by the FGFR3 biomarker population, physician familiarity, and post-checkpoint treatment demand. Growth depends on broader use in earlier lines or combination regimens.

The principal downside risks are:

• PADCEV and other antibody-drug conjugates taking share.
• Low FGFR3 testing rates.
• Short treatment duration.
• Ocular and metabolic toxicity.
• Failure of earlier-line clinical development.
• Generic entry before the projected mid-2030s patent horizon.

The product is strategically valuable to J&J as a precision-oncology asset, but it is unlikely to become one of the company’s largest pharmaceutical franchises without a materially broader label.

Key Takeaways

• BALVERSA is erdafitinib, an oral FGFR inhibitor for FGFR3-altered advanced urothelial carcinoma.
• FDA approval is concentrated in patients previously treated with a PD-1 or PD-L1 inhibitor.
• Sales rose materially after the 2023 label expansion, reaching an estimated $250 million to $300 million range in 2024.
• The addressable market is limited by FGFR3 prevalence, testing rates, prior treatment requirements, and competition from PADCEV.
• Patent protection is expected to extend into the mid-2030s, with the final generic-entry date dependent on Orange Book listings and litigation.
• BALVERSA faces generic rather than biosimilar risk.
• No major publicly disclosed Paragraph IV settlement has established an earlier U.S. generic launch date.
• The main commercial upside is earlier-line or combination use; the main risk is competitive displacement before patent expiry.

FAQs

Is BALVERSA a blockbuster drug?

No. BALVERSA is a commercially meaningful targeted-oncology product, but reported annual sales remain below the $1 billion blockbuster threshold.

Does BALVERSA require genetic testing?

Yes. FDA-approved use requires identification of susceptible FGFR3 alterations using an FDA-approved companion diagnostic or an appropriately validated testing approach.[1]

Can BALVERSA be substituted with a biosimilar?

No. Erdafitinib is a small molecule. Any follow-on product would generally be an ANDA generic, not a biosimilar.

What is the most important competitor to BALVERSA?

PADCEV is the most important commercial competitor because it treats a broader urothelial-cancer population and has expanded into earlier treatment settings.

What would most increase BALVERSA revenue?

An FDA-approved first-line indication, a successful combination regimen, or broader use before or alongside checkpoint inhibitors would produce the largest potential market expansion.

References

1. U.S. Food and Drug Administration. (2024). BALVERSA (erdafitinib) prescribing information. FDA.

2. Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R. A., Burgess, E. F., Fleming, M. T., Rezazadeh, A., Niegisch, G., et al. (2023). Erdafitinib in locally advanced or metastatic urothelial carcinoma. The New England Journal of Medicine, 389(21), 1961-1971.

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Astex Pharmaceuticals. (2012). Astex and Janssen Biotech enter collaboration to discover and develop novel cancer therapeutics. Astex Pharmaceuticals.

5. Johnson & Johnson. (2023). Annual report for the fiscal year ended December 31, 2023. Johnson & Johnson.

6. Johnson & Johnson. (2024). Annual report for the fiscal year ended December 29, 2024. Johnson & Johnson.

DrugChatter Q&A for BALVERSA

Can Balversa treat bladder cancer?